Abstract
Cell autonomous antiviral defenses can inhibit the replication of viruses and reduce transmission and disease severity. To better understand the antiviral response to SARS-CoV-2, we used interferon-stimulated gene (ISG) expression screening to reveal that OAS1, through RNase L, potently inhibits SARS-CoV-2. We show that while some people can express a prenylated OAS1 variant, that is membrane-associated and blocks SARS-CoV-2 infection, other people express a cytosolic, nonprenylated OAS1 variant which does not detect SARS-CoV-2 (determined by the splice-acceptor SNP Rs10774671). Alleles encoding nonprenylated OAS1 predominate except in people of African descent. Importantly, in hospitalized patients, expression of prenylated OAS1 was associated with protection from severe COVID-19, suggesting this antiviral defense is a major component of a protective antiviral response. Remarkably, approximately 55 million years ago, retrotransposition ablated the OAS1 prenylation signal in horseshoe bats (the presumed source of SARS-CoV-2). Thus, SARS-CoV-2 never had to adapt to evade this defense. As prenylated OAS1 is widespread in animals, the billions of people that lack a prenylated OAS1 could make humans particularly vulnerable to the spillover of coronaviruses from horseshoe bats.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC MR/V028448/1 to MP and SJW) and the MRC via the following grants, MR/ K024752/1(to SJW), MC_UU_12014/10 (to MP and SJW) and MR/P022642/1 (to SJW and SJR), MR/V000489/1 (to ECYW and RJS), MR/S00971X/1 (to RJS and ECYW), MR/P001602/1 (to ECYW), MR/V011561/1 (to PJL). Support was also provided by a Wellcome Principal Research Fellowship 210688/Z/18/Z (to PJL), a Wellcome Trust Fellowship 201366/Z/16/Z (to SJR), the Addenbrookes Charitable Trust and the NIHR Cambridge Biomedical Research Centre (to PJL), support from the German Research Foundation, Deutsche Forschungsgemeinschaft; project number 406109949 (to VH), and German Federal Ministry of Food and Agriculture through BMEL Forderkennzeichen: 01KI1723G (to VH), and a Daphne Jackson Fellowship funded by Medical Research Scotland (to SS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the South Central-Oxford C Research Ethics Committee in England (reference 13/SC/0149), and by the Scotland A Research Ethics Committee (reference 20/SS/0028). The study was registered at https://www.isrctn.com/ISRCTN66726260. This work (ethics approval number 32077020.6.0000.0005) was approved on May 2020 by the National Committee in Ethics and Research, Brazil. in COMISSAO NACIONAL DE ETICA EM PESQUISA.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data included or available upon final publication (unless prevented by ethical or legal constraints).
